Meeting
2022 ASCO Annual Meeting
A phase II study of gemcitabine docetaxel combination in metastatic/unresectable locally advanced relapsed synovial sarcoma.
Authors
Ghazal Tansir
All India Institute of Medical Science (AIIMS), Delhi, India
Ghazal Tansir , Sameer Rastogi , akash kumar , Shamim Ahmed Shamim , Rambha Panday , Adarsh Barwad , Ekta Dhamija
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
CTRI/2020/02/023612
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11554)
DOI
10.1200/JCO.2022.40.16_suppl.11554
Abstract #
11554
Poster Bd #
458
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.
First Author: Andrew Eugene Hendifar
Poster
2023 ASCO Annual Meeting
Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.
First Author: Nadezhda Omelchenko
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2022 ASCO Annual Meeting
GALLANT: A phase 2 study using metronomic gemcitabine, doxorubicin, nivolumab, and docetaxel as second/third-line therapy for advanced sarcoma (NCT04535713).
First Author: Noufil Adnan